BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25268386)

  • 1. Effect of the potent CYP2D6 inhibitor sarpogrelate on the pharmacokinetics and pharmacodynamics of metoprolol in healthy male Korean volunteers.
    Cho DY; Bae SH; Lee JK; Park JB; Kim YW; Lee S; Oh E; Kim BT; Bae SK
    Xenobiotica; 2015 Mar; 45(3):256-63. PubMed ID: 25268386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
    Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
    J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
    Rabinovich-Guilatt L; Steiner L; Hallak H; Pastino G; Muglia P; Spiegelstein O
    Br J Clin Pharmacol; 2017 Oct; 83(10):2214-2224. PubMed ID: 28449367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
    Parker RB; Soberman JE
    Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition.
    Athukuri BL; Neerati P
    Drug Metab Pers Ther; 2016 Dec; 31(4):229-234. PubMed ID: 27875319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Subjects: A Comparison of Controlled-Release Sarpogrelate and Immediate-Release Sarpogrelate.
    Lee SY; Kim JR; Jung JA; Kim TE; Lee SY; Huh W; Lee JW; Jun H; Ko JW
    Pharmacology; 2015; 96(1-2):68-75. PubMed ID: 26089136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the pharmacokinetic properties of the oral sarpogrelate hydrochloride controlled-release tablet in healthy male Korean subjects.
    Jung JA; Kim JR; Kim TE; Lee SY; Huh W; Lee JW; Jun H; Ko JW
    Clin Ther; 2013 Jul; 35(7):1038-44. PubMed ID: 23870611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
    Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
    Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
    Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
    Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
    Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
    Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
    Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
    J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
    Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
    Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
    Wang Y; Zhou L; Dutreix C; Leroy E; Yin Q; Sethuraman V; Riviere GJ; Yin OQ; Schran H; Shen ZX
    Br J Clin Pharmacol; 2008 Jun; 65(6):885-92. PubMed ID: 18384443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.
    Koch HJ; Hartmann M; Bliesath H; Huber R; Steinijans VW; Mascher H; Wurst W
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):420-3. PubMed ID: 8897078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
    Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
    J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.